These hospital leaders fell from grace, and the dean ate 16 million yuan in kickbacks! Medical anti-corruption upgrade, equipment secretary | field | medicine
More than a hundred hospital directors and secretaries have been investigated
An instrument was eaten by the dean with a rebate of 16 million yuan
……
recently
Exposed by the Central Commission for Discipline Inspection
A linear accelerator will receive a rebate of 16 million yuan
Related topics trending on hot searches
Triggering heated discussions
With the issue of corruption in the national pharmaceutical industry
Convening of a video conference on centralized rectification work
A battle against the pharmaceutical industry
Full domain, full chain, and full coverage
The anti-corruption storm has officially kicked off
Over 150 hospital deans and secretaries have fallen from grace
In the past week, a strong anti-corruption campaign has deterred the entire pharmaceutical industry.
On the evening of July 31st, "Snake Venom Killer" Salon Biotech announced that one of Salon Biotech's actual controllers, Chairman, and legal representative Fan Zhihe, was detained and investigated for suspected crimes related to his position.
On August 5, the Xizang Discipline Inspection and Supervision Network released news that Tang Rongke, secretary of the Party Committee of the Xizang Autonomous Region Tibetan Hospital, was suspected of serious violations of discipline and was currently under disciplinary review and supervision by the Xizang Autonomous Region Commission for Discipline Inspection.
On August 7th, "Qingfeng Jieyang" announced that Zhang Zhuangquan, former Secretary of the Party Group and Director of the Health Bureau in Jiexi County, had been expelled from the Party and his retirement benefits revoked due to serious violations of discipline and law.
In recent years, against the backdrop of the continuous increase in anti-corruption efforts in the pharmaceutical industry, hospital deans and secretaries have become targets of scrutiny, especially since the beginning of this year, the anti-corruption storm has become increasingly fierce.
Under the continuous high-pressure crackdown, a group of hospital leaders and key personnel have been gradually taken down. According to incomplete media statistics, from the beginning of this year to the end of July, at least 155 hospital directors, secretaries, and other major leaders were investigated nationwide. In addition, many department heads have been investigated. Among them, some secretaries and deans of grassroots hospitals have experienced the phenomenon of "petty officials and huge greed".
A device director receives a rebate of 16 million yuan
Commercial bribery has always been an "open secret" in the pharmaceutical industry, but with the increasing efforts of regulatory authorities to investigate and deal with commercial bribery cases, some pharmaceutical companies have begun to adopt more covert and complex measures to put a "legal coat" on their bribery behavior. On the one hand, enterprises penetrate the hospital through various channels in order to gain higher market share. On the other hand, high kickbacks also make suppliers and agents complain that they are not fed enough.
△ Xinhua News Agency Information Map
In May of this year, the Central Commission for Discipline Inspection and the National Supervisory Commission exposed a corruption case: Yang Wenjun, former Deputy Secretary of the Party Committee and President of the People's Hospital of Pu'er City, Yunnan Province, and Yang Wenhong, former Party Committee member and Vice President, became sworn brothers with suppliers, indulging in eating, entertainment, and accepting gifts and cash. When the hospital was discussing the purchase of a medical device linear accelerator with an import price of 15 million yuan, other members of the hospital leadership team clearly opposed it, but Yang Wenjun insisted on purchasing it and ultimately reached an agreement. In the end, the hospital bought for 35.2 million yuan, and Yang Wenjun ate a rebate of 16 million yuan.
Under the influence of Yang Wenjun, the middle-level cadres of the hospital acted from top to bottom, calculated independently, and illegally profited from their power. In the end, the former director of the finance department, Liu Mouwen, the former director of the logistics service department, Zhang Mousheng, and the former director of the medical equipment department, Ye Mouguang, and other department heads were all filed for review and investigation, with a involved amount of tens of millions of yuan.
Experts have pointed out that in response to the issue of corruption in the pharmaceutical industry, hospitals should strengthen democratic supervision internally, relevant departments should strengthen audit supervision and inspection efforts, and establish a comprehensive regulatory system with multiple approaches. At the same time, it is necessary to strengthen supervision in areas such as drug procurement, personnel arrangements, and engineering construction, especially actively supervise the implementation of various laws, regulations, policy provisions, and systems in these areas, and supervise the exercise of power under the sunshine.
Multiple pharmaceutical academic conferences announced postponement
According to Caixin News Agency, eight organizers, including the Hematology Branch of the Chinese Medical Association, Shaanxi Medical Association, and Guangxi Medical Association, have recently announced the postponement of relevant academic conferences. According to incomplete statistics, in just a few days since August, at least 10 upcoming academic conferences and forums in the pharmaceutical industry have been announced to be postponed. In addition, some study and training courses have also been announced to be postponed recently.
However, some industry insiders have raised objections to the claim that academic conferences are generally postponed. Liu Jun, Deputy Secretary General of the County Health Development Research Center, wrote on his WeChat Moments, "I have also consulted multiple industry associations and obtained some information from their Moments that some academic conferences may have been postponed or cancelled recently. However, more compliant academic activities are being carried out as scheduled. Compliant academic activities have never been the subject of anti-corruption and rectification actions. I hope industry friends can think independently and not be confused by biased information."
"Of course, academic conferences cannot be equated directly with 'corruption'. Academic conferences have made many contributions to sharing cutting-edge knowledge in related fields, understanding new treatment concepts, and so on. However, in my judgment, the intensity of this anti-corruption storm is unprecedented, and it is not ruled out that the number of academic conferences in the industry will show a cliff like decline in the future. For a long time, 'unnecessary meetings' will become an industry consensus." Senior medical reform expert Xu Yucai finally predicted.
Pharmaceutical enterprises become the "storm eye" of anti-corruption
Multiple listed companies have made statements
The industry pointed out that due to the clear focus of this concentrated rectification on key links and "key minorities" in the pharmaceutical industry, such as production, supply, sales, use, and reimbursement, pharmaceutical enterprises have become the "storm eye" of anti-corruption.
△ Xinhua News Agency Information Map
According to incomplete statistics by reporters, as of August 7th, more than 20 listed companies have made statements on anti-corruption. From the response, most pharmaceutical companies emphasize that the company has always operated in compliance, and the impact of anti-corruption on the company is relatively small. Some pharmaceutical companies also point out that medical anti-corruption is a necessary process for the industry to return to normal order, which is conducive to the long-term development of the industry.
Although several companies, including Hengrui Pharmaceutical, have responded, the A-share pharmaceutical sector has still suffered collectively in recent times.
At the same time, some pharmaceutical representatives are also feeling a bit restless. According to media reports, in a chat group in a pharmaceutical industry where journalists are diving, many pharmaceutical representatives are sharing the latest anti-corruption trends in their respective provinces.
Correcting unhealthy practices in the field of pharmaceutical purchasing and sales and medical services
13 departments including Guangdong Provincial Health Commission issued a document
On August 2nd, the official website of the Guangdong Provincial Health Commission issued a notice on adjusting the member units and division of responsibilities of the Guangdong Province Joint Mechanism for Correcting Unhealthy Practices in the Field of Medical Purchasing and Sales and Medical Services, stating that the Guangdong Province Joint Mechanism for Correcting Unhealthy Practices in the Field of Medical Purchasing and Sales and Medical Services will be adjusted.
The new joint working mechanism consists of 13 departments, including the Provincial Health Commission, Provincial Department of Education, Provincial Department of Industry and Information Technology, Provincial Department of Public Security, Provincial Department of Finance, Provincial Department of Commerce, Provincial Audit Office, Provincial State owned Assets Supervision and Administration Commission, Provincial Taxation Bureau, Provincial Market Supervision and Administration Bureau, Provincial Medical Insurance Bureau, Provincial Traditional Chinese Medicine Bureau, and Provincial Drug Administration. Offices are established at the Provincial Health Commission.
In terms of specific division of labor, the Provincial Administration for Market Regulation is responsible for strengthening the investigation and handling of cases of unfair competition in the pharmaceutical industry; Strengthen the supervision of price behavior in the fields of drugs and medical services, and carry out price supervision and inspection and anti-monopoly law enforcement in accordance with the law; Actively promote the revision of local regulations in conjunction with the Anti Unfair Competition Law, and guide industries to operate in accordance with the law and regulations. The Provincial Medical Insurance Bureau is responsible for continuously promoting pharmaceutical pricing and procurement credit evaluation in accordance with relevant management authorities, and promoting centralized procurement of drugs and medical consumables; Strengthen the supervision of relevant behaviors and medical expenses included in the payment scope of the medical security fund.
Source | Comprehensive CCTV, China News Network, Surging News, Daily Economic News, Caixin News Agency
